UPCOMING EVENT
Cell & Gene Meeting on the Mesa
Location: 2400 E Missouri Ave, Phoenix, AZ 85016
Oct. 06, 2025
FIND OUT MORE
Location: 2400 E Missouri Ave, Phoenix, AZ 85016
Oct. 06, 2025
FIND OUT MOREARM commends the U.S. Food and Drug Administration for its decision to eliminate the Risk Evaluation and Mitigation Strategies (REMS) program and reduce other labeling restrictions for autologous CAR-T cell therapies. This evidence-based decision significantly lowers barriers for physicians administering and patients seeking these transformative treatments.
In June 2025, ARM and CEOs from 30 + cell and gene therapy companies issued a joint call to EU leaders urging them that Europe must seize this once-in-a-generation opportunity to bring transformative therapies to patients. Our call to action features a policy blueprint with recommendations to make this a reality.
ARM is deeply disappointed to learn that Office of Therapeutic Products (OTP) Director Nicole Verdun and Deputy Director Rachael Anatol have been placed on administrative leave.
ARM, the International Society for Cell & Gene Therapy, and the American Society for Gene & Cell Therapy today called for a ten-year global moratorium on heritable human genome editing.
Regenerative medicine includes gene therapies, cell therapies, and tissue-engineered products intended to augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes in the body.
Regenerative medicine aims to alter the current practice of medicine by treating the root causes of disease and disorders.
ARM is the global voice of the cell and gene therapy sector, representing more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.
As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis.